Endpoints News 27. März 2026 Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
Endpoints News 25. März 2026 Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
Endpoints News 23. März 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Endpoints News 20. März 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 16. März 2026 After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B
Endpoints News 26. Feb. 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 20. Feb. 2026 Novartis to divest India unit to private equity-led consortium for $159M
Endpoints News 18. Feb. 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News 18. Feb. 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 13. Jan. 2026 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News 12. Jan. 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s